<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640118</url>
  </required_header>
  <id_info>
    <org_study_id>H-15004078</org_study_id>
    <nct_id>NCT02640118</nct_id>
  </id_info>
  <brief_title>The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects</brief_title>
  <acronym>Px-Lixi</acronym>
  <official_title>The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects -a Delineation of Extrapancreatic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postprandial glucose (PPG) excursions are not only determined by insulin-mediated glucose
      disposal and endogenous glucose production (regulated by insulin and glucagon); also the rate
      of gastric emptying constitutes an important determinant of PPG levels 1. The short-acting
      glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide is used in the treatment of
      type 2 diabetes. It increases glucose-dependent insulin secretion, suppresses glucagon
      secretion and reduces gastric emptying of meals 2. These three mechanisms most likely
      constitute the weightiest mechanisms behind the potent impact of lixisenatide on exaggerated
      PPG excursions in patients with type 2 diabetes - which often are normalised during
      lixisenatide treatment 3. However, the separate impact of lixisenatide-induced reduction of
      gastric emptying (independently of the pancreatic effects) has been difficult to determine.
      Importantly, treatment with lixisenatide also decreases appetite and food intake and may,
      like native GLP-1, increase energy expenditure 4. So far an exact demarcation of the
      pancreatic and extrapancreatic effects of lixisenatide in humans remains to be established.

      The present project serves to determine whether effects of lixisenatide on gastric emptying,
      appetite, food intake and resting energy expenditure are dependent on the endocrine pancreas.

      The study is a randomised, placebo-controlled, double-blinded, cross-over study.

      12 healthy persons and 12 pancreatectomized patients (i.e. patients who have had their
      pancreata removed due to pancreatic cancer or severe chronic pancreatitis) will be subjected
      to two experimental days on which they will undergo a liquid meal test followed by a fasting
      period and finished off with an ad libitum meal with lixisenatide and placebo, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PPG excursions measured as incremental area under curve (iAUC)</measure>
    <time_frame>-120,-45,-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>differences in gastric emptying, measurement of s-paracetamol</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
    <description>measurement of time to peak and incremental area under the curve (iAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>food intake and appetite</measure>
    <time_frame>at time 0,30,60,90,120,150,180 minutes</time_frame>
    <description>assessed by a visual analogue scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting energy expenditure (REE)</measure>
    <time_frame>-90,30,150 minutes</time_frame>
    <description>measured by calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>p-glucose mmol/L</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>s-insulin pmol/L</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>p-C-peptide pmol/l</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon, gastrin, cholecystokinin, GIP, GLP-1, oxyntomodulin and GLP-2.</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>free fatty acids</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibroblast growth factor 21</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>p-triglyceride mmol/l</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ghrelin</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peptide YY</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes After Total Pancreatectomy</condition>
  <arm_group>
    <arm_group_label>Pancreatectomised + Lixisenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
Before the meal a Lixisenatide-injection will be given subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatectomized + lixisenatide-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
Before the meal a placebo-injection will be given subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy + Lixisenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
Before the meal a Lixisenatide-injection will be given subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy + lixisenatide-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
Before the meal a placebo-injection will be given subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide</intervention_name>
    <description>single injection of 20 Âµg lixisenatide subcutaneously</description>
    <arm_group_label>Pancreatectomised + Lixisenatide</arm_group_label>
    <arm_group_label>Healthy + Lixisenatide</arm_group_label>
    <other_name>Lyxumia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide-Placebo</intervention_name>
    <arm_group_label>Pancreatectomized + lixisenatide-placebo</arm_group_label>
    <arm_group_label>Healthy + lixisenatide-placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized liquid meal</intervention_name>
    <description>standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).</description>
    <arm_group_label>Pancreatectomised + Lixisenatide</arm_group_label>
    <arm_group_label>Pancreatectomized + lixisenatide-placebo</arm_group_label>
    <arm_group_label>Healthy + Lixisenatide</arm_group_label>
    <arm_group_label>Healthy + lixisenatide-placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria Pancreatectomised patients

          -  Caucasians above 18 years of age who have undergone total pancreatectomy

          -  Normal haemoglobin

          -  Informed consent Healthy subjects

          -  Normal fasting plasma glucose (FPG) and normal HbA1C (according to the World Health
             Organization (WHO) criteria)

          -  Normal haemoglobin

          -  Age above 18 years

          -  Informed consent

        Exclusion criteria Pancreatectomised patients

          -  Inflammatory bowel disease

          -  Operation within the last 3 months

          -  Ongoing chemotherapy or chemotherapy within the last 3 months

          -  Ostomy

          -  Nephropathy (serum creatinine &gt;150 ÂµM and/or albuminuria)

          -  Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate
             aminotransferase (ASAT) &gt;3Ãnormal values)

          -  Pregnancy and/or breastfeeding

          -  Age above 80 years

          -  Any condition that the investigator feels would interfere with trial participation
             Healthy subjects

          -  Diabetes mellitus (DM)

          -  Prediabetes (impaired glucose tolerance and/or impaired FPG)

          -  First degree relatives with DM

          -  Inflammatory bowel disease

          -  Intestinal resection and/or ostomy

          -  Nephropathy (serum creatinine &gt;150 ÂµM and/or albuminuria

          -  Liver disease (ALAT and/or serum ASAT &gt;2Ãnormal values)

          -  Pregnancy and/or breastfeeding

          -  Age above 80 years

          -  Any condition that the investigator feels would interfere with trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Diabetes Research, Gentofte Hospital, Kildegaardsvej 28, 2900 Hellerup, Denmark</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Associated Professor, MD, P.h.D.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

